BR112021025425A2 - Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre - Google Patents

Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre

Info

Publication number
BR112021025425A2
BR112021025425A2 BR112021025425A BR112021025425A BR112021025425A2 BR 112021025425 A2 BR112021025425 A2 BR 112021025425A2 BR 112021025425 A BR112021025425 A BR 112021025425A BR 112021025425 A BR112021025425 A BR 112021025425A BR 112021025425 A2 BR112021025425 A2 BR 112021025425A2
Authority
BR
Brazil
Prior art keywords
mammalian cell
cre recombinase
producing
polypeptide
recombinant mammalian
Prior art date
Application number
BR112021025425A
Other languages
English (en)
Inventor
Simon Auslaender
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021025425A2 publication Critical patent/BR112021025425A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre. no presente documento é relatado um método para produzir uma célula de mamífero recombinante compreendendo um ácido desoxirribonucleico que codifica um polipeptídeo e que secreta o polipeptídeo compreendendo as etapas de a) fornecer uma célula de mamífero compreendendo uma sequência de nucleotídeos exógenos integrada em um único local dentro de um locus do genoma da célula de mamífero; b) introduzir na célula fornecida em a) uma composição de dois ácidos desoxirribonucleicos compreendendo três sequências de reconhecimento de recombinação diferentes e um a oito cassetes de expressão; c) introduzir mrna de recombinase cre e d) selecionar células que expressam o segundo marcador de seleção e secretam o polipeptídeo, produzindo, assim, uma célula de mamífero recombinante compreendendo um ácido desoxirribonucleico que codifica o polipeptídeo e que secreta o polipeptídeo, em que o mrna de recombinase cre é a única fonte de recombinase cre no método.
BR112021025425A 2019-06-19 2020-06-17 Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre BR112021025425A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181099 2019-06-19
PCT/EP2020/066688 WO2020254357A1 (en) 2019-06-19 2020-06-17 Method for the generation of a protein expressing cell by targeted integration using cre mrna

Publications (1)

Publication Number Publication Date
BR112021025425A2 true BR112021025425A2 (pt) 2022-02-01

Family

ID=67060259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025425A BR112021025425A2 (pt) 2019-06-19 2020-06-17 Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre

Country Status (11)

Country Link
US (1) US20220170049A1 (pt)
EP (1) EP3986928A1 (pt)
JP (1) JP7410983B2 (pt)
KR (1) KR20220010024A (pt)
CN (1) CN114080451B (pt)
AU (1) AU2020294880B2 (pt)
BR (1) BR112021025425A2 (pt)
CA (1) CA3140297A1 (pt)
IL (1) IL288966A (pt)
MX (1) MX2021015536A (pt)
WO (1) WO2020254357A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117305334A (zh) * 2022-06-21 2023-12-29 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6114600A (en) * 1997-10-31 2000-09-05 The United States Of America As Represented By The Secretary Of Agriculture Resolution of complex integration patterns to obtain single copy transgenes
JP2001086989A (ja) * 1999-09-17 2001-04-03 Univ Osaka 哺乳類型Ｃｒｅリコンビナーゼ遺伝子
EP1253823A4 (en) * 1999-12-27 2005-07-20 Chengyu Liu CONTROL OF THE PERCENTUAL FREEDOM OF GENDER AFFAIRS BY TRANSGENIC TRANSMISSIONS TO THE GENDER CHROMOSOMES
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
CN1392260A (zh) * 2002-05-16 2003-01-22 林忠平 采用两套重组系统删除特定外源基因的方法
EA014182B1 (ru) 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101431319B1 (ko) 2009-05-27 2014-08-20 에프. 호프만-라 로슈 아게 삼중특이성 또는 사중특이성 항체
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
DK3147362T3 (en) * 2009-10-29 2019-04-08 Regeneron Pharma Multifunctional alleles
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9528124B2 (en) * 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
SI2726510T1 (sl) 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dvojno ciljanje
WO2013006142A1 (en) 2011-07-05 2013-01-10 Nanyang Technological University A novel process and reagent for rapid genetic alterations in eukaryotic cells
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
SG11201510297QA (en) * 2013-06-19 2016-01-28 Sigma Aldrich Co Llc Targeted integration
EP3408396A4 (en) * 2016-01-26 2019-10-09 Cedars-Sinai Medical Center IN VIVO DOUBLE RECOMBINASE MEDIATION (DRMCE) CASSETTE EXCHANGE SYSTEMS AND METHODS AND MODELS OF ASSOCIATED DISEASES
BR112018071285A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método
AU2018232698B2 (en) 2017-03-10 2020-06-25 F. Hoffmann-La Roche Ag Method for producing multispecific antibodies
AU2018392728A1 (en) * 2017-12-22 2020-07-09 Genentech, Inc. Targeted integration of nucleic acids

Also Published As

Publication number Publication date
IL288966A (en) 2022-02-01
CN114080451B (zh) 2024-03-22
AU2020294880B2 (en) 2024-05-02
MX2021015536A (es) 2022-02-10
US20220170049A1 (en) 2022-06-02
CA3140297A1 (en) 2020-12-24
WO2020254357A1 (en) 2020-12-24
JP7410983B2 (ja) 2024-01-10
EP3986928A1 (en) 2022-04-27
KR20220010024A (ko) 2022-01-25
JP2022537203A (ja) 2022-08-24
CN114080451A (zh) 2022-02-22
AU2020294880A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
BR112019027750A2 (pt) Bibliotecas transcriptônicas de célula única altorendimento, e métodos de fabricação e de usos
Von Meyenn et al. Impairment of DNA methylation maintenance is the main cause of global demethylation in naive embryonic stem cells
MX2023010271A (es) Secuenciacion de celulas individuales de alto rendimiento con sesgo de amplificacion reducido.
AU2017257225A1 (en) Allele editing and applications thereof
RU2018112325A (ru) Последовательности 3'-utr для стабилизации рнк
CL2018001198A1 (es) Métodos y composiciones para edición génica en hemocitoblastos
AR100216A1 (es) Edición de genes multiplexados
CO7151523A2 (es) Método y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
AR083432A1 (es) Precursor de microarn y metodos para regular la expresion del gen objetivo
BR112012017267A2 (pt) ácidos graxos de cadeia ramificada dispersos e produção biológica dos mesmos
BR112015031639A2 (pt) integração alvo
AR103446A1 (es) Método para modificar con precisión una planta a través de la expresión transitoria de genes
AR102888A1 (es) Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47
BR112015009812A2 (pt) Método para a inserção genética específica em um genoma de planta, célula de planta transformada e seu uso, planta resistente a herbicidas, kit, vetor, e célula hospedeira
BR112021021075A2 (pt) Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
BR112021025425A2 (pt) Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
BR112022003970A2 (pt) Métodos e composições para integração genômica
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
CO2022010430A2 (es) Método para el tratamiento del síndrome de usher y composición del mismo
BR112022003093A2 (pt) Produção de células t a partir de ipscs de rag inativado
Song et al. The effects of kinase modulation on in vitro maturation according to different cumulus-oocyte complex morphologies
AU2016363746A1 (en) Method for determining cell clonality
BR112019005605A2 (pt) métodos para modificar o genoma (nuclear) de uma célula vegetal e um gene epsps endógeno ou para produzir uma célula vegetal ou para testar a eficiência de edição de genoma, bactéria, e, vetor
BRPI1006628B8 (pt) método para produzir uma enzima lipolítica